Literature DB >> 29742291

PD-1 and PD-L1 expression in HNSCC primary cancer and related lymph node metastasis - impact on clinical outcome.

Sven Schneider1, Lorenz Kadletz1, Robert Wiebringhaus2, Lukas Kenner2,3,4, Edgar Selzer5, Thorsten Füreder6, Orsolya Rajky6, Anna S Berghoff6, Matthias Preusser6, Gregor Heiduschka1.   

Abstract

AIMS: Expression profiles and clinical impact of programmed cell death ligand 1 (PD-L1) and programmed cell death 1 (PD-1) expressing tumour infiltrating lymphocytes (TILs) in head and neck squamous cell carcinoma (HNSCC) are not elucidated fully. This study evaluates expression patterns in primary HNSCC and related lymph node metastasis and the impact on patients' clinical outcome. METHODS AND
RESULTS: Immunohistochemical staining patterns of PD-L1 and PD-1 were evaluated in 129 specimens of primary HNSCC and 77 lymph node metastases. Results were correlated with patients' clinical data. PD-L1 expression was observed in 36% of primary carcinoma and 33% of lymph node metastasis, and correlates significantly with decreased overall survival (OS) (P = 0.01) and disease-free survival (DFS) (P = 0.001) in oral cavity squamous cell carcinoma patients. PD-L1 expression was associated with presence of lymph node metastasis (P = 0.0223). Infiltration of PD-1-expressing lymphocytes correlates significantly with favourable OS (P = 0.001) and DFS (P = 0.001) in oropharyngeal cancer and hypopharyngeal cancer patients OS (P = 0.007) and DFS (P = 0.001). Presence of PD-1 TILs also correlates significantly with better OS (P = 0.005) and DFS (P = 0) in the human papilloma virus (HPV)-negative cohort. Cox regression multivariate analysis revealed PD-1 TIL expression as an independent prognostic marker for OS (P = 0.004) and DFS (P = 0.001) and T stage was validated as negative prognostic marker for OS (P = 0.011). PD-1-expressing lymphocytes (P = 0.0412) and PD-L1 expression (P = 0.0022) patterns correlate significantly in primary cancers and matched lymph node metastases.
CONCLUSIONS: Our results characterise the expression profiles of PD-1 axis proteins in HNSCC which might serve as possible clinical prognostic markers.
© 2018 John Wiley & Sons Ltd.

Entities:  

Keywords:  HNSCC; PD-1; PD-L1; TIL; immunohistochemistry; lymph node metastasis

Mesh:

Substances:

Year:  2018        PMID: 29742291     DOI: 10.1111/his.13646

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  29 in total

1.  Effects of Tobacco Smoking on the Tumor Immune Microenvironment in Head and Neck Squamous Cell Carcinoma.

Authors:  Janis V de la Iglesia; Robbert J C Slebos; Laura Martin-Gomez; Xuefeng Wang; Jamie K Teer; Aik Choon Tan; Travis A Gerke; Garrick Aden-Buie; Tessa van Veen; Jude Masannat; Ritu Chaudhary; Feifei Song; Michelle Fournier; Erin M Siegel; Matthew B Schabath; J Trad Wadsworth; Jimmy Caudell; Louis Harrison; Bruce M Wenig; Jose Conejo-Garcia; Juan C Hernandez-Prera; Christine H Chung
Journal:  Clin Cancer Res       Date:  2019-12-17       Impact factor: 12.531

2.  CD47 expression in gastric cancer clinical correlates and association with macrophage infiltration.

Authors:  Mingsu Shi; Yun Gu; Kaifeng Jin; Hanji Fang; Yifan Chen; Yifan Cao; Xin Liu; Kunpeng Lv; Xudong He; Chao Lin; Hao Liu; He Li; Hongyong He; Jing Qin; Ruochen Li; Heng Zhang; Weijuan Zhang
Journal:  Cancer Immunol Immunother       Date:  2021-01-03       Impact factor: 6.968

Review 3.  The role of transforming growth factor-beta in immune suppression and chronic inflammation of squamous cell carcinomas.

Authors:  Alexander A Strait; Xiao-Jing Wang
Journal:  Mol Carcinog       Date:  2020-04-17       Impact factor: 4.784

4.  PD-L1 expression in head and neck carcinoma by combined positive score: a comparison among preoperative biopsy, tumor resection, and lymph node metastasis.

Authors:  Andrea Ambrosini-Spaltro; Francesco Limarzi; Michele Gaudio; Sebastiano Calpona; Giuseppe Meccariello
Journal:  Virchows Arch       Date:  2022-04-14       Impact factor: 4.064

5.  A novel comprehensive immune-related gene signature as a promising survival predictor for the patients with head and neck squamous cell carcinoma.

Authors:  Ruihua Fang; Muhammad Iqbal; Lin Chen; Jing Liao; Jierong Luo; Fanqin Wei; Weiping Wen; Wei Sun
Journal:  Aging (Albany NY)       Date:  2021-04-17       Impact factor: 5.682

Review 6.  Tumor immune microenvironment in head and neck cancers.

Authors:  Samantha M Y Chen; Alexandra L Krinsky; Rachel A Woolaver; Xiaoguang Wang; Zhangguo Chen; Jing H Wang
Journal:  Mol Carcinog       Date:  2020-02-03       Impact factor: 4.784

7.  PD-L1 expression, tumor-infiltrating lymphocytes, mismatch repair deficiency, EGFR alteration and HPV infection in sinonasal squamous cell carcinoma.

Authors:  Takahiro Hongo; Hidetaka Yamamoto; Rina Jiromaru; Ryuji Yasumatsu; Ryosuke Kuga; Yui Nozaki; Kazuki Hashimoto; Mioko Matsuo; Takahiro Wakasaki; Akihiro Tamae; Kenichi Taguchi; Satoshi Toh; Muneyuki Masuda; Takashi Nakagawa; Yoshinao Oda
Journal:  Mod Pathol       Date:  2021-07-03       Impact factor: 7.842

8.  Explant Modeling of the Immune Environment of Head and Neck Cancer.

Authors:  Shay Sharon; Thomas Duhen; Shelly Bambina; Jason Baird; Rom Leidner; Bryan Bell; Nardy Casap; Marka Crittenden; Swetha Vasudevan; Maria Jubran; Nataly Kravchenko-Balasha; Michael Gough
Journal:  Front Oncol       Date:  2021-06-17       Impact factor: 6.244

9.  Correlation between vascular endothelial growth factor pathway and immune microenvironment in head and neck squamous cell carcinoma.

Authors:  Chao Zhu; Liqun Gu; Zelong Liu; Jiang Li; Mianfeng Yao; Changyun Fang
Journal:  BMC Cancer       Date:  2021-07-20       Impact factor: 4.430

10.  Immune landscape and subtypes in primary resectable oral squamous cell carcinoma: prognostic significance and predictive of therapeutic response.

Authors:  Pengfei Diao; Yue Jiang; Yuanyuan Li; Xiang Wu; Jin Li; Chen Zhou; Lei Jiang; Wei Zhang; Enshi Yan; Ping Zhang; Xu Ding; Heming Wu; Hua Yuan; Jinhai Ye; Xiaomeng Song; Linzhong Wan; Yunong Wu; Hongbing Jiang; Yanling Wang; Jie Cheng
Journal:  J Immunother Cancer       Date:  2021-06       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.